Revised MRPs of 1,364 anti-cancer formulations come into effect; consumers to save ₹3,540 crore/year

The National Pharmaceutical Pricing Authority (NPPA) recently implemented revised Maximum Retail Prices (MRPs) for 1,364 anti-cancer medications, effective November 9, 2026. This change is anticipated to save consumers approximately ₹3,540.38 crore per year, according to an official announcement.

The price adjustments were introduced following recommendations from an Expert Committee, which convened on October 17, 2026. The committee's suggestions were put forth by the Directorate General of Health Services (DGHS), under the Ministry of Health & Family Welfare, to the NPPA, which operates under the Department of Pharmaceuticals.

Out of the 1,364 formulations, 85 pharmaceutical companies have reported revised MRPs for 1,364 drugs as of November 8, 2026. Of these, 679 brands have witnessed price reductions exceeding 50%, with the most significant cut reaching 96.45%. The Ministry of Chemicals and Fertilizers: Department of Pharmaceuticals detailed this information in a recent release.

Health experts have applauded the reduction in prices, highlighting the excessive pricing that previously existed in the market. They argue that sharp cuts in the cost of cancer drugs expose the need for further action to improve affordability and accessibility.

Consumers can verify medicine rates through multiple channels, including the revised MRP printed on product packs, the Pharma Sahi Daam mobile application, and the official NPPA website (nppa.gov.in). They can also report instances of overcharging or other pricing-related issues via the Pharma Jan Samadhan portal or by contacting the NPPA helpline at 1800-111-255.